AIM-001
- Generic Name
- AIM-001
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
Phase 2
Recruiting
- Conditions
- Solid Tumor, AdultSarcomaSarcoma,Soft TissueChondrosarcomaCancerNeoplasms
- Interventions
- Drug: Checkpoint Inhibitor, Immune
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- EpicentRx, Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT04673942
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸California Cancer Associates for Research and Excellence, cCARE, San Marcos, California, United States
🇺🇸Providence Saint John's Health Center, Santa Monica, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath